Pin Therapeutics
- Biotech or pharma, therapeutic R&D
Pin Therapeutics is a biotech company focused on developing novel E3 ligases and molecular glue degraders for the treatment of hematological cancers and solid tumors. Utilizing a next-generation TPD platform, the company targets otherwise undruggable sites with minimal off-target effects, and is seeking strategic partners for the co-development of its first-in-class CK1a molecular glue degrader, PIN 5018 (IND submitted in April 2025) which aims to treat Colorectal Cancer, Adenoid Cystic Carcinoma (ACC), and RR-AML. Out pipeline includes seven discovery programs targeting KRAS and six other targets. Pin Therapeutics boasts advanced capabilities for rapid ligand discovery and has developed a novel assay for MGD screening. They focus on leveraging their unique E3 ligase platforms to explore synergies for effective cancer therapies, while actively optimizing ligands for targeted degradation of specific proteins. *NO SERVICE PROVIDER REQUESTS, thanks!
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}